WRBC
HUMA icon

W.R. Berkley Corp’s Humacyte HUMA Stock Holding History

W.R. Berkley Corp’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-41,838
Closed -$426K – 450
2021
Q2 		$426K Hold
41,838
– – 0.04% 280
2021
Q1 		$453K Sell
41,838
-188,848
-82% -$2.06M 0.05% 240
2020
Q4 		$2.35M Buy
+230,686
New +$2.29M 0.39% 55

Other funds holding HUMA

YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

W.R. Berkley Corp's HUMA Position: Q3 2021 in Review

W.R. Berkley Corp sold out of Humacyte (HUMA) in Q3 2021, closing a stake of 41,838 shares — an estimated $426K sold.

W.R. Berkley Corp first reported a position in HUMA in Q4 2020 and held it in 3 quarters. The position peaked at $2.35M in Q4 2020. 32 funds tracked by Wall St. Rank hold HUMA as of Q3 2021.

  • W.R. Berkley Corp reported no remaining Humacyte position as of Q3 2021 after selling out during the quarter.
  • W.R. Berkley Corp sold 41,838 Humacyte shares in Q3 2021, an estimated $426K.
  • W.R. Berkley Corp first reported a position in Humacyte in Q4 2020 and held it in 3 quarters.
  • W.R. Berkley Corp's Humacyte position peaked at $2.35M in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Humacyte as of Q3 2021.

Based on W.R. Berkley Corp's 13F filing for Q3 2021, filed 15 Nov 2021.